視網膜藥物市場規模、佔有率和成長分析（按成分、適應症、劑型、通路和地區分類）－2026-2033年產業預測

預計到 2024 年，全球視網膜治療市場規模將達到 218.6 億美元，到 2025 年將達到 236.5 億美元，到 2033 年將達到 444.2 億美元，預測期（2026-2033 年）的複合年成長率為 8.2%。

由於全球視網膜疾病（尤其是老齡化黃斑部病變(AMD)、糖尿病視網膜病變和視網膜靜脈阻塞 (RVO)）的盛行率不斷上升，視網膜治療市場正經歷顯著成長。這些疾病影響著全球數百萬人的健康。人口老化、糖尿病患者數量的增加以及眼科診斷和治療可近性的提高，都在推動市場擴張。抗 VEGF 療法，特別是 aflavercept、ranibizumab 和 brolucizumab，是主導市場收入成長的主要因素，其中 aflavercept 的銷售額尤為突出。緩釋給藥系統和基因療法等創新技術正在革新治療方法，有效解決慢性病患者難以堅持注射頻率等難題。主要企業正致力於開發更持久的治療方法、雙重抑制策略和先進的玻璃體內植入，進而為視網膜疾病的治療帶來更有效的未來。

全球視網膜治療市場按藥物類別、適應症、製劑形式、用途、通路和地區細分。依藥物類別分類，可分為抗血管內皮生長因子（VEGF）藥物、皮質類固醇、免疫調節劑、基因及細胞療法、小分子療法及其他。依適應症分類，可分為老齡化黃斑部病變、糖尿病視網膜病變、葡萄膜炎等。依劑型分類，可分為注射劑、植入、眼藥水、口服藥錠/膠囊及軟膏/凝膠。依通路分類，可分為醫院藥房、零售藥房和線上藥房。按地區分類，可分為北美、歐洲、亞太、中東和非洲以及拉丁美洲。

推動全球視網膜治療市場發展的因素

視網膜疾病（例如老齡化黃斑部病變(AMD)、糖尿病視網膜病變 (DR) 和視網膜靜脈阻塞 (RVO)）的快速成長是全球視網膜治療市場的主要驅動力。這些疾病影響數百萬患者，且盛行率持續上升，導致大量患者亟需有效的視網膜治療方法。人口老化、糖尿病發病率上升、不良飲食習慣以及螢幕使用時間增加等因素共同加劇了視網膜健康問題，從而推動了對創新療法的需求。眼科醫療服務的可近性提高也增強了人們對這些疾病的認知，進而推動了對介入療法（例如抗 VEGF 藥物、皮質類固醇和先進基因療法）的需求。

限制全球視網膜治療市場發展的因素

全球視網膜治療市場面臨許多限制因素，其中視網膜治療費用高昂尤為突出，嚴重限制了患者的可及性，尤其是在中低收入地區。治療多種視網膜疾病所必需的標準抗VEGF藥物，其價格往往超出許多患者的承受能力。儘管存在一些生物相似藥可供選擇，但對許多醫療系統和個人而言，這些藥物仍然是一項巨大的經濟挑戰。此外，長期治療方案會加重病患和醫療服務提供者的經濟負擔。開發中國家的許多公共醫療系統難以承擔這些治療方法的資金籌措，而私人保險計劃往往限制承保範圍或收取高額自付費用，從而阻礙患者堅持治療。

全球視網膜藥物市場趨勢

全球視網膜治療市場正經歷著向基因療法的重大轉變，預計將徹底改變目前缺乏有效治療方案的遺傳性視網膜疾病的治療現況。這種創新方法專注於利用腺結合病毒（AAV）的載體實現持久的治療效果，從而實現抗血管內皮生長因子（VEGF）的持續表達。主要市場參與者正在推進有前景的候選藥物的研發，特別是那些針對罕見視網膜營養不良的藥物，從而提升了這些治療方法的戰略價值。獲得孤兒藥資格認定的吸引力，加上單劑量給藥的潛力以及強力的定價策略，鞏固了基因療法作為未來視網膜治療領域核心組成部分的地位，並推動了相關投資和研究的舉措。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 價值鏈分析
• 監管機構
• 研發線產品分析
• 案例研究

全球視網膜藥物市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 抗 VEGF 藥物
  • VEGF-A拮抗劑
  • 雙標靶抗血管新生藥物
• 皮質類固醇
  • 玻璃體內植入
  • 注射用懸浮液
• 免疫調節劑
• 基因和細胞療法
• 小分子療法
• 其他藥物類別

全球視網膜藥物市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 老齡化黃斑部病變
• 糖尿病視網膜病變
• 葡萄膜炎
• 其他

全球視網膜藥物市場規模（依劑型及複合年成長率分類）（2026-2033 年）

• 注射（溶液、混懸液）
• 植入（可生物分解、不可生物分解）
• 眼藥水
• 口服片劑/膠囊
• 軟膏和凝膠

全球視網膜藥物市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球視網膜藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Roche Holding AG（incl. Genentech）
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Allergan（AbbVie Inc.）
• Alcon Inc.
• Santen Pharmaceutical Co., Ltd.
• MeiraGTx Holdings plc
• Ocuphire Pharma, Inc.
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.
• Oxurion NV
• Graybug Vision, Inc.
• Clearside Biomedical, Inc.
• Outlook Therapeutics, Inc.
• Iveric Bio（acquired by Astellas Pharma）
• Sandoz（a Novartis spin-off for biosimilars）
• Coherus BioSciences, Inc.
• Biogen Inc.

結論與建議

Global Retinal Drugs Market size was valued at USD 21.86 Billion in 2024 and is poised to grow from USD 23.65 Billion in 2025 to USD 44.42 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global retinal drugs market is experiencing significant growth driven by the increasing prevalence of retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), which collectively affect millions globally. The ageing population and rising diabetes rates, alongside improved access to ophthalmic diagnostics and therapies, are propelling market expansion. Anti-VEGF treatments, particularly aflibercept, ranibizumab, and brolucizumab, dominate market revenue, with aflibercept leading sales. Innovations such as sustained-release drug delivery systems and gene therapies are revolutionizing treatment approaches, addressing challenges like injection frequency compliance in chronic conditions. Key players are focusing on developing longer-lasting therapies, dual-inhibition strategies, and advanced intravitreal implants, shaping a more effective future for retinal disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Drugs Market Segments Analysis

The global Retinal Drugs market is segmented on the basis of Drug Classes, Indication, Formulation, Application, Distribution Channel and region. By Drug Classes, the market is segmented into Anti-VEGF Agents, Corticosteroids, Immunomodulators, Gene & Cell Therapies, Small Molecule Therapies, and Others. By Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. Based on Formulation, the market is segmented into Injectables, Implants, Eye Drops, Oral Tablets/Capsules, and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Retinal Drugs Market

The rapid rise in retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) significantly propels the expansion of the global retinal drugs market. With millions affected by these conditions and their prevalence steadily increasing, a large patient base is seeking effective retinal therapies. Contributing factors such as aging populations, diabetes prevalence, poor dietary habits, and heightened screen time have compounded the issues related to retinal health, leading to a greater demand for innovative treatments. Improved access to eye care has also heightened awareness of these diseases, increasing the need for interventions like anti-VEGF medications, corticosteroids, and advanced gene therapies.

Restraints in the Global Retinal Drugs Market

The Global Retinal Drugs market faces substantial constraints due to the prohibitive costs associated with retinal treatments, which severely limit accessibility, especially in low- and middle-income regions. The standard anti-VEGF medications, essential for treating various retinal conditions, are often priced at levels that many patients cannot afford. Although some biosimilar options exist, they still represent a financial challenge for numerous healthcare systems and individuals. Furthermore, the long durations of treatment regimens can exacerbate the economic burden on patients and healthcare providers alike. Many public healthcare systems in developing nations struggle to fund or reimburse these therapies, while private insurance plans frequently restrict coverage or impose high copays, discouraging patient compliance.

Market Trends of the Global Retinal Drugs Market

The Global Retinal Drugs market is witnessing a significant shift towards gene therapy, which is poised to revolutionize treatment for inherited retinal diseases lacking effective solutions. This innovative approach focuses on delivering long-lasting therapeutic effects through AAV-based vectors, enabling sustained anti-VEGF expression. Prominent market players are advancing promising candidates, particularly for rare retinal dystrophies, thereby enhancing the strategic value of these therapies. The allure of orphan drug designations, coupled with the potential for one-time dosing and robust pricing strategies, solidifies gene therapy's position as a pivotal element in the future landscape of retinal care, driving investment and research initiatives.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Value Chain Analysis
• Regulatory Bodies
• Pipeline Product Analysis
• Case Studies

Global Retinal Drugs Market Size by Drug Classes & CAGR (2026-2033)

• Market Overview
• Anti-VEGF Agents
  • VEGF-A Antagonists
  • Dual-target Anti-angiogenic Agents
• Corticosteroids
  • Intravitreal Implants
  • Injectable Suspensions
• Immunomodulators
• Gene & Cell Therapies
• Small Molecule Therapies
• Other Drug Classes

Global Retinal Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Drugs Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectables (Solutions, Suspensions)
• Implants (Biodegradable, Non-biodegradable)
• Eye Drops
• Oral Tablets/Capsules
• Ointments & Gels

Global Retinal Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Retinal Drugs Market Size & CAGR (2026-2033)

• North America (Drug Classes, Indication, Formulation, Distribution Channel)
  • US
  • Canada
• Europe (Drug Classes, Indication, Formulation, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Classes, Indication, Formulation, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Classes, Indication, Formulation, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Classes, Indication, Formulation, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Holding AG (incl. Genentech)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio (acquired by Astellas Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (a Novartis spin-off for biosimilars)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations